Literature DB >> 2953796

Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.

G Forni, M Giovarelli, A Santoni, A Modesti, M Forni.   

Abstract

Daily local administration at the tumor challenge site of 10 injections of 10 U of recombinant interleukin 2 (IL 2) obtained from different factories induces a consistent, though limited inhibition of the growth of CE-2, a poorly immunogenic methylcholanthrene-induced tumor. By contrast, almost complete tumor inhibition is observed when these injections are performed in mice challenged with tumor cells admixed at 1:5 cell ration with nylon wool column purified lymphocytes obtained from tumor-bearing animals. The host immune system plays a fundamental role in this lymphokine-activated tumor inhibition (LATI), which is derived from the local combination of IL 2 and nonreactive lymphocytes. When the host is sublethally irradiated, or the reactivity of L3T4 and Asialo GM1 lymphocytes is suppressed by in vivo antibody treatment, in fact, LATI no longer takes place. Daily injections of antibody to murine interferon-gamma or cyclosporin A have the same effect, indicating that lymphokine release plays an important role in the recruitment of host reactivity. The morphological data show that when LATI is taking place the tumor challenge area becomes infiltrated by mononuclear cells and granulocytes (mostly eosinophils), which establish close contacts with each other and with tumor cells as determined at ultrastructural analysis. Tumor draining lymph nodes display marked expansion of cortical and paracortical areas. Lymphocyte proliferation, interferon-gamma release and cytotoxicity against CE-2 and YAC-1 target cells are greatly enhanced during LATI. Contralateral lymph nodes and the spleen also show a slight increment of these functions. In mice challenged with CE-2 tumor cells only and receiving daily IL 2 injections, these reaction functions (with the exception of interferon-gamma secretion) are also enhanced, though to a lesser extent than during LATI and only in tumor-draining lymph nodes. Last, the growth of a second contralateral tumor challenge is significantly impaired during or after LATI, showing that a persistent and effective systemic reactivity can be quickly induced in this way.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953796

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 3.  Lymphokine activated killer cells.

Authors:  A Lindemann; F Herrmann; W Oster; R Mertelsmann
Journal:  Blut       Date:  1989-10

4.  An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.

Authors:  J C Becker; N Varki; S D Gillies; K Furukawa; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.

Authors:  R A Maas; D H Van Weering; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.

Authors:  C Fortis; E Ferrero; C Besana; M Biffi; S Heltai; L Galli; A Borri; A Schoenheit; C Rugarli
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Histologic and immunohistochemical characterization of tumor and inflammatory infiltrates in oral squamous cell carcinomas treated with local multikine immunotherapy: the macrophage at the front line.

Authors:  Meora Feinmesser; Elimelech Okon; Ariel Schwartz; Ella Kaganovsky; Britta Hardy; Elena Aminov; Ben Nageris; Jaqueline Sulkes; Raphael Feinmesser
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-24       Impact factor: 2.503

8.  Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes.

Authors:  Y Haga; M A Tempero; D Kay; R K Zetterman
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

9.  Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.

Authors:  L T Balemans; V Mattijssen; P A Steerenberg; B E Van Driel; P H De Mulder; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

10.  Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival.

Authors:  In Gab Jeong; Kyung Seok Han; Jae Young Joung; Woo Suk Choi; Seung Sik Hwang; Seung Ok Yang; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.